SLC11A1 (formerly NRAMP1) and disease resistance.
| dc.Faculty | Endemic Diseases | en_US |
| dc.contributor.author | Blackwell, Jenefer M. | |
| dc.contributor.author | Peacock, Christopher | |
| dc.contributor.author | Ibrahim, Muntaser E. | |
| dc.contributor.author | etal. | |
| dc.contributor.editor | en_US | |
| dc.contributor.other | Molecular Biology | en_US |
| dc.date | 2001-12 | |
| dc.date.accessioned | 2015-11-12T12:11:29Z | |
| dc.date.available | 2015-11-12T12:11:29Z | |
| dc.date.issued | 2015-11-12 | |
| dc.date.submitted | 2015 | |
| dc.description.abstract | Slc11a1 (formerly Nramp1) has many pleiotropic effects on macrophage (mf) activation, including regulation of the CXC chemokine KC, interleukin-1b (IL-1b), inducible nitric oxide synthase (iNOS), major histocompatibility complex (MHC) class II molecules, tumour necrosis factor a (TNFa), nitric oxide (NO) release, L-arginine flux, oxidative burst and tumoricidal as well as antimicrobial activity (reviewed by Blackwell and Searle, 1999; Blackwell et al., 2000). A naturally occurring Gly!Asp mutation at amino acid 169 of Slc11a1 makes mice as susceptible to Leishmania donovani, Salmonella typhimurium and Mycobacterium bovis as gene-disrupted mice (Vidal et al., 1995). Hence, the mutation is a functional null. This mutation also confers susceptibility to a range of other pathogens in mice, including Mycobacterium lepraemurium (Brown et al., 1982; Skamene et al., 1984), Mycobacterium intracellulare (Goto et al., 1989), Toxoplasma gondii (Blackwell et al., 1994), Candida albicans (Puliti et al., 1995) and Leishmania infantum (Leclercq et al., 1996). | en_US |
| dc.identifier.uri | http://khartoumspace.uofk.edu/123456789/17051 | |
| dc.language.iso | en | en_US |
| dc.publisher | UOFK | en_US |
| dc.subject | SLC11A1 (formerly NRAMP1) | en_US |
| dc.subject | disease resistance | en_US |
| dc.title | SLC11A1 (formerly NRAMP1) and disease resistance. | en_US |
| dc.type | Publication | en_US |